AllPennyStocks.com Wall Street Analysts Were Busy This Morning

Wall Street Analysts Were Busy This Morning

Wall Street Analysts Were Busy This Morning By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, December 4, 2024

There was quite a bit of analyst action driving pricing of penny stocks so far during Wednesday’s premarket hours. In case you missed them, we decided to highlight a couple of exciting examples. 

Shares of Absci Corporation (Nasdaq:ABSI) are currently bid up at $3.08/share (+3.01% implied open for sellers) following JonesTrading initiating coverage of the company with a buy rating and a $9 price target. 

Background: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Up next we have shares of Heron Therapeutics Inc. (Nasdaq:HRTX), which are currently bid up at $1.94/share (+64.41% implied open for sellers). This move is due to Needham reiterating their buy rating and maintaining their $4 price target following yesterday’s announcement that the company got a favorable patent dispute ruling. 

Background: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.


Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

News of Lithium Project LOI Sends Canadian Shares Higher
Shares of Uranium Explorer Higher on New Purchase
This Biotech Found Significant Success Following Key Announcement
Most Popular


Back to Top